Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 17/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 16/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 16/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 16/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 16/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 16/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 12/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 9/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | GABRP | O00591 | 1/20 | 0.80 |
| ▸ | GABRD | O14764 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.80 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | GABRE | P78334 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235492 | 0.92 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL10632058 | 0.91 | GABRG2 (0.83) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL11940827 | 0.90 | GABRA1 (0.83) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Flumazenil SCHEMBL11885881 | 0.89 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Flumazenil SCHEMBL16187025 | 0.89 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL20747040 | 0.89 | GABRA1 (0.80) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Flumazenil SCHEMBL79030 | 0.89 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Ro-151310 SCHEMBL5748925 | 0.89 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL14610311 | 0.89 | GABRA1 (0.80) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Flumazenil SCHEMBL29746432 | 0.89 | GABRG2 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049554-A1 | HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES | NEW YORK UNIVERSITY (US) | 2025-03-06 | — | — | WO | claimed |
| US-20250075218-A1 | HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES | NEW YORK UNIVERSITY (US) | 2025-03-06 | — | — | US | claimed |
| US-12410318-B2 | Pigment composition, colorant composition, coating material, ink, ink set, printed matter, and packaging material | ARTIENCE CO., LTD. (JP) | 2025-09-09 | — | — | US | disclosed |
| CN-119751669-A | P-Tau217 antibody and humanized reconstruction and application thereof | 福建医科大学附属协和医院 | 2025-04-04 | — | — | CN | disclosed |
| US-20250075218-A1 | HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES | NEW YORK UNIVERSITY (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025049554-A1 | HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES | NEW YORK UNIVERSITY (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240343907-A1 | PIGMENT COMPOSITION, COLORANT COMPOSITION, COATING MATERIAL, INK, INK SET, PRINTED MATTER, AND PACKAGING MATERIAL | ARTIENCE CO., LTD. (JP) | 2024-10-17 | — | — | US | disclosed |
| EP-4382450-A1 | PIGMENT COMPOSITION, COLORANT COMPOSITION, PAINT, INK, INK SET, PRINTED ARTICLE, AND PACKAGING MATERIAL | artience Co., Ltd. (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-117813355-A | Pigment compositions, coloring compositions, coatings, inks, ink sets, prints and packaging materials | 爱天思株式会社 | 2024-04-02 | — | — | CN | disclosed |
| US-10206921-B2 | Methods and compositions for treating a subject for central nervous system (CNS) injury | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206921-B2 | Methods and compositions for treating a subject for central nervous system (CNS) injury | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-19 | — | — | US | disclosed |
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | GABRA5, GABRA6, GABRB1 | GABRA1 4/4885GABRG2 15/4885GABRB3 6/4885 |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | GABRA5, GABRA6, GABRA1 | GABRA1 3/4885GABRG2 16/4885GABRB3 10/4885 |
| US-10206921-B2 | Methods and compositions for treating a subject for central nervous system (CNS) injury | GABBR2, GABBR1, GABRR3 | GABRA1 14/4885GABRG2 13/4885GABRB3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.